C. Demerlé

发表

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia

S. Granjeaud, D. Olive, A. Cerwenka, 2017, Oncotarget.

Chronic hepatitis E in absence of severe immune deficiency.

P. Colson, F. Vély, N. Schleinitz, 2020, Clinics and research in hepatology and gastroenterology.

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

D. Olive, B. Malissen, J. Nunès, 2022, bioRxiv.

Imbalance of Circulating Innate Lymphoid Cell Subpopulations in Patients With Septic Shock

F. Vély, C. Farnarier, N. Banzet, 2019, Front. Immunol..

Screening platelet function in blood donors

M. Alessi, C. Falaise, J. Chiaroni, 2022, Transfusion.

High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome

S. Granjeaud, D. Olive, D. Blaise, 2021, Proceedings of the National Academy of Sciences.

Mixed Streptococcus pneumoniae and Streptococcus pyogenes meningitis in an immunocompromised adult patient: a case report

M. Drancourt, R. Costello, V. Ivanov, 2015, Journal of Medical Case Reports.

High-dimensional mass cytometry analysis of NK cell alterations in Acute Myeloid Leukemia identifies a subgroup with adverse clinical outcome

S. Granjeaud, D. Olive, D. Blaise, 2020, medRxiv.

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia

S. Granjeaud, D. Olive, A. Toubert, 2017, Front. Immunol..

BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer

D. Olive, L. Gorvel, C. Demerle, 2021, Frontiers in Oncology.

The Role of Platelet‐Activating Factor in Cerebral Ischemia and Related Disorders

P. Braquet, D. Hosford, B. Spinnewyn, 1989, Annals of the New York Academy of Sciences.

[Revelation of a polymicrocystic ovary syndrome after one month's treatment by pulsatile GnRH in a patient presenting with functional hypothalamic amenorrhea].

D. Dewailly, A. Reyss, C. Demerle, 2003, Gynecologie, obstetrique & fertilite.

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

D. Olive, B. Malissen, J. Nunès, 2023, Journal for ImmunoTherapy of Cancer.